Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

doi:10.1128/JVI.75.13.5721-5729.2001

Review

. 2001 Jul;75(13):5721-9.

doi: 10.1128/JVI.75.13.5721-5729.2001.

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

J P Moore¹, P W Parren, D R Burton

Affiliations

PMID: 11390574
PMCID: PMC114288
DOI: 10.1128/JVI.75.13.5721-5729.2001

Review

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

J P Moore et al. J Virol. 2001 Jul.

. 2001 Jul;75(13):5721-9.

doi: 10.1128/JVI.75.13.5721-5729.2001.

Authors

J P Moore¹, P W Parren, D R Burton

Affiliation

¹ Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Ave., New York, NY 10021, USA. jpm2003@med.cornell.edu

PMID: 11390574
PMCID: PMC114288
DOI: 10.1128/JVI.75.13.5721-5729.2001

No abstract available

PubMed Disclaimer

Cited by

Molecular epidemiology of HIV-1 clades in Southern Brazil.
Raboni SM, Almeida SM, Rotta I, Ribeiro CE, Rosario D, Vidal LR, Nogueira MB, Riedel M, Winhescki Mda G, Ferreira KA, Ellis R. Raboni SM, et al. Mem Inst Oswaldo Cruz. 2010 Dec;105(8):1044-9. doi: 10.1590/s0074-02762010000800015. Mem Inst Oswaldo Cruz. 2010. PMID: 21225203 Free PMC article.
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.
Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, Fuller JT, Kunstman KJ, Sutter G, Montefiori DC, Erfle V, Desrosiers RC, Wilson N, Picker LJ, Wolinsky SM, Wang C, Allison DB, Watkins DI. Horton H, et al. J Virol. 2002 Jul;76(14):7187-202. doi: 10.1128/jvi.76.14.7187-7202.2002. J Virol. 2002. PMID: 12072518 Free PMC article. Clinical Trial.
Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Beddows S, Schülke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP. Beddows S, et al. J Virol. 2005 Jul;79(14):8812-27. doi: 10.1128/JVI.79.14.8812-8827.2005. J Virol. 2005. PMID: 15994775 Free PMC article.
Unraveling clinical outcomes of long-term cART treatment in HIV-1 patients with or without the Brazilian GWGR motif in the V3 loop.
Folgosi VÂ, Komninakis SV, Lopes L, Monteiro MA, Assone T, Fonseca LAM, Domingues W, Leite Junior PD, Victor JR, Casseb J. Folgosi VÂ, et al. Rev Inst Med Trop Sao Paulo. 2024 Jul 8;66:e38. doi: 10.1590/S1678-9946202466038. eCollection 2024. Rev Inst Med Trop Sao Paulo. 2024. PMID: 39052025 Free PMC article.
A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
Zwick MB, Kelleher R, Jensen R, Labrijn AF, Wang M, Quinnan GV Jr, Parren PW, Burton DR. Zwick MB, et al. J Virol. 2003 Jun;77(12):6965-78. doi: 10.1128/jvi.77.12.6965-6978.2003. J Virol. 2003. PMID: 12768015 Free PMC article.

See all "Cited by" articles

References

1. Artenstein A W, VanCott T C, Mascola J R, Carr J K, Hegerich P A, Gaywee J, Sanders-Buell E, Robb M L, Dayhoff D E, Thitivichianlert S. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis. 1995;171:805–810. - PubMed
1. Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook P J, Simmonds P, Weber J. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 1998;79:77–82. - PubMed
1. Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed
1. Berman P W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14(Suppl. 3):S277–S289. - PubMed
1. Berman P W, Gray A M, Wrin T, Vennari J C, Eastman D J, Nakamura G R, Fancis D P, Gorse G, Schwartz D H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997;176:384–397. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

[1] Artenstein A W, VanCott T C, Mascola J R, Carr J K, Hegerich P A, Gaywee J, Sanders-Buell E, Robb M L, Dayhoff D E, Thitivichianlert S. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis. 1995;171:805–810. - PubMed

[2] Artenstein A W, VanCott T C, Mascola J R, Carr J K, Hegerich P A, Gaywee J, Sanders-Buell E, Robb M L, Dayhoff D E, Thitivichianlert S. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis. 1995;171:805–810. - PubMed

[3] Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook P J, Simmonds P, Weber J. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 1998;79:77–82. - PubMed

[4] Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook P J, Simmonds P, Weber J. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 1998;79:77–82. - PubMed

[5] Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed

[6] Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed

[7] Berman P W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14(Suppl. 3):S277–S289. - PubMed

[8] Berman P W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14(Suppl. 3):S277–S289. - PubMed

[9] Berman P W, Gray A M, Wrin T, Vennari J C, Eastman D J, Nakamura G R, Fancis D P, Gorse G, Schwartz D H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997;176:384–397. - PubMed

[10] Berman P W, Gray A M, Wrin T, Vennari J C, Eastman D J, Nakamura G R, Fancis D P, Gorse G, Schwartz D H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997;176:384–397. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

Affiliation

Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development

Authors

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources